Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease
- PMID: 27082314
- DOI: 10.1097/SHK.0000000000000633
Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease
Abstract
In response to infectious and, in some instances, noninfectious insults, the affected tissues/cells of the host undergo inflammation. However, uncontrolled inflammation could be detrimental to the host, resulting in inflammatory disease, such as inflammatory lung disease. Although the etiology of the disease is well defined, the underling pathogenesis is still incompletely understood. The renin-angiotensin system (RAS), one of the primary cardiovascular regulatory systems, has been proposed to be involved in the pathogenesis of inflammatory lung disease. In particular, the RAS has been implicated as advances in the understanding of the multifunctionality of individual components of the system have been made, and by the fact that the RAS acts not only systemically, but also locally in a variety of tissues, including the lung. Angiotensin-converting enzyme 2 (ACE2), a relatively new member of the RAS, has drawn extensive attention since 2003, because of the findings that ACE2 is the receptor for SARS Corona virus and that maintenance of normal ACE2 levels in the lung is beneficial for the host to combat inflammatory lung disease. Nevertheless, the mechanism through which ACE2 plays a role in inflammatory lung disease has not been clearly identified. In an attempt to summarize current literature findings and progress made in uncovering the role of ACE2 in inflammatory lung disease, this review will focus on recent studies examining pulmonary ACE2 biology, its roles in inflammatory lung disease pathogenesis and possible underlying mechanisms. Finally, we will discuss pulmonary ACE2 as a potential therapeutic target for inflammatory lung disease.
Similar articles
-
ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.J Cardiovasc Pharmacol. 2015 Dec;66(6):540-50. doi: 10.1097/FJC.0000000000000307. J Cardiovasc Pharmacol. 2015. PMID: 26322922 Free PMC article. Review.
-
Angiotensin-converting enzyme-2 overexpression attenuates inflammation in rat model of chronic obstructive pulmonary disease.Inhal Toxicol. 2014 Jan;26(1):14-22. doi: 10.3109/08958378.2013.850563. Inhal Toxicol. 2014. PMID: 24417403
-
Lessons from SARS: control of acute lung failure by the SARS receptor ACE2.J Mol Med (Berl). 2006 Oct;84(10):814-20. doi: 10.1007/s00109-006-0094-9. Epub 2006 Sep 19. J Mol Med (Berl). 2006. PMID: 16988814 Free PMC article. Review.
-
Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis.Circ J. 2010 Mar;74(3):405-10. doi: 10.1253/circj.cj-10-0045. Epub 2010 Feb 4. Circ J. 2010. PMID: 20134095 Review.
-
Osthole Alleviates Bleomycin-Induced Pulmonary Fibrosis via Modulating Angiotensin-Converting Enzyme 2/Angiotensin-(1-7) Axis and Decreasing Inflammation Responses in Rats.Biol Pharm Bull. 2016;39(4):457-65. doi: 10.1248/bpb.b15-00358. Epub 2016 Jan 28. Biol Pharm Bull. 2016. PMID: 26822530
Cited by
-
Smoking and COVID-19: A Scoping Review.Tob Use Insights. 2021 Feb 15;14:1179173X21994612. doi: 10.1177/1179173X21994612. eCollection 2021. Tob Use Insights. 2021. PMID: 33642886 Free PMC article. Review.
-
Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19.Cytometry A. 2020 Sep;97(9):872-881. doi: 10.1002/cyto.a.24190. Epub 2020 Aug 21. Cytometry A. 2020. PMID: 32686260 Free PMC article. Review.
-
Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases.Clin Exp Allergy. 2020 Dec;50(12):1313-1324. doi: 10.1111/cea.13746. Epub 2020 Oct 6. Clin Exp Allergy. 2020. PMID: 32975865 Free PMC article. Review.
-
Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial.Adv Pharm Bull. 2022 Aug;12(4):641-644. doi: 10.34172/apb.2022.067. Epub 2021 Oct 6. Adv Pharm Bull. 2022. PMID: 36415639 Free PMC article.
-
A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics.Nat Biomed Eng. 2021 Aug;5(8):815-829. doi: 10.1038/s41551-021-00718-9. Epub 2021 May 3. Nat Biomed Eng. 2021. PMID: 33941899 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous